Drug intelligence / Profile preview

BBT-031

Development stage: Preclinical
Lead developer: Bolder Biotechnology
Administration: Intravenous

Overview

BBT-031 is a preclinical drug candidate developed by Bolder BioTechnology, Inc. It is being investigated for the treatment of short stature and lipodystrophy. The development of BBT-031 received financial support through grants from the U.S. Department of the Treasury under the Qualifying Therapeutic Discovery Project Tax Credit Program, covering up to 50% of qualifying expenses incurred in 2009 and 2010.

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on BBT-031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBT-031.

Explore the full profile